OpenOnco · Treatment Plan

Treatment plan — Acute Myeloid Leukemia

PLAN-VERIFIED-AML-L2-AML_2L_IDH2_ENASIDENIB-V1 · v1 · 2026-07-15

Patient

VERIFIED-AML-L2-AML_2L_IDH2_ENASIDENIB · Algorithm: ALGO-AML-2L

DiagnosisAcute Myeloid Leukemia

MOH / ICD-10C92.0

ICD-O-39861/3; C42.1

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

Primary current-line option

Aggressive plan

★ DEFAULT

Indication

IND-AML-2L-IDH2-ENASIDENIB

Regimen

Enasidenib monotherapy for R/R IDH2-mutated AML

Drugs + NSZU

Enasidenib (DRUG-ENASIDENIB) 100 mg PO once daily · continuous, 28-day cycles, until progression / unacceptable toxicity · PO ✗ Not registered in UA

Supportive care

SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS

Reason

Primary current-line option selected by ALGO-AML-2L at step 5; branch-driving red flag: RF-AML-IDH2-MUT-ACTIONABLE.

Other current-line alternatives (3 tracks)

Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.

Aggressive plan

Indication

IND-AML-2L-GILTERITINIB-FLT3

Regimen

Gilteritinib monotherapy for R/R FLT3-mutated AML

Drugs + NSZU

Gilteritinib (DRUG-GILTERITINIB) 120 mg PO once daily · continuous, 28-day cycles, until progression / unacceptable toxicity · PO ✗ Not registered in UA

Supportive care

SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS

Reason

Current-line alternative presented for HCP consideration

Aggressive plan

Indication

IND-AML-2L-KMT2A-REVUMENIB

Regimen

Revumenib monotherapy for R/R KMT2A-rearranged AML

Drugs + NSZU

Revumenib (DRUG-REVUMENIB) 163 mg PO q12h with strong CYP3A inhibitor (cobicistat) co-administration; OR 270 mg PO q12h without CYP3A inhibitor · continuous, 28-day cycles, until progression / unacceptable toxicity / proceed to alloHCT in CR · PO ✗ Not registered in UA

Supportive care

SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS

Reason

Current-line alternative presented for HCP consideration

Standard plan

Indication

IND-AML-1L-VEN-AZA

Regimen

Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule

Drugs + NSZU

Venetoclax (DRUG-VENETOCLAX) Cycle 1 ramp: day 1 = 100 mg, day 2 = 200 mg, day 3 = 400 mg → days 4-28 = 400 mg PO daily; subsequent cycles = 400 mg daily continuously · PO daily; reduce to ~70-100 mg if combined with strong CYP3A4 inhibitor (posaconazole) · PO ⚠ NSZU — not for this indication
Azacitidine (DRUG-AZACITIDINE) 75 mg/m²/day · SC or IV days 1-7 of each 28-day cycle · SC ⚠ NSZU — not for this indication

Supportive care

SUP-TLS-PROPHYLAXIS, SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS

Reason

Current-line alternative presented for HCP consideration

Why this branch was chosen

Triggers from the patient profile that fired and drove the chosen branch.

Step 5 → branch IND-AML-2L-IDH2-ENASIDENIB

RF-AML-IDH2-MUT-ACTIONABLE ★ winner: IDH2 R140Q or R172K activating mutation in AML — ~8-12% prevalence. Enasidenib (IDHIFA / IDHENTIFY — phase-3 R/R AML; monotherapy ORR 38%, CR 19%) is FDA-approved for R/R-AML-IDH2; also active 1L combination with azacitidine in unfit (AG221-AML-005 — ORR 71%). SRC-NCCN-AML-2025SRC-ELN-AML-2022SRC-ESMO-AML-2020

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-BM-ASPIRATE	Bone Marrow Aspirate	Critical	histology	—	all tracks
TEST-BM-TREPHINE	Bone Marrow Trephine	Critical	histology	—	all tracks
TEST-CBC	Complete Blood Count with Differential	Critical	lab	—	all tracks
TEST-CMP	Comprehensive Metabolic Panel	Critical	lab	—	all tracks
TEST-COAG-PANEL	Coagulation Panel	Critical	lab	—	all tracks
TEST-FISH-PANEL	FISH (Fluorescence In Situ Hybridization)	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-FLOW-CYTOMETRY	Flow Cytometry	Critical	histology	CSD Lab ✓ (code TBC)	all tracks
TEST-HBV-SEROLOGY	Hepatitis B Serology Panel (HBsAg, anti-HBc total, anti-HBs)	Critical	lab	—	all tracks
TEST-HCV-ANTIBODY	HCV Antibody	Critical	lab	—	all tracks
TEST-HIV-SEROLOGY	HIV Antibody/Antigen	Critical	lab	—	all tracks
TEST-KARYOTYPE	Karyotype	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-LDH	Lactate Dehydrogenase	Critical	lab	—	all tracks
TEST-LFT	Liver Function Tests (ALT, AST, bilirubin, ALP, GGT, albumin)	Critical	lab	—	all tracks
TEST-NGS-MYELOID-PANEL	Myeloid NGS Panel	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-PERIPHERAL-SMEAR	Peripheral Blood Smear	Critical	lab	CSD Lab ✓ (code TBC)	standard
TEST-ECHO	Echocardiography	Standard	imaging	—	aggressive
TEST-URIC-ACID	Serum Uric Acid	Standard	lab	—	all tracks

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

AML emergency triad: hyperleukocytosis (WBC ≥100 K/μL), tumor lysis syndrome (LDH >2× ULN, uric acid >7.5 mg/dL, K+ rising, phosphate rising, Ca2+ falling), or symptomatic leukostasis (dyspnea, altered mental status, retinal hemorrhage)
Triggers HOLD on regimen selection until emergency stabilization: cytoreduction with hydroxyurea ± leukapheresis, IV hydration + rasburicase / allopurinol for TLS, electrolyte correction, urgent ICU/heme consult. Plan generation does not…
RF-AML-EMERGENCY-TLS-LEUKOSTASISSRC-NCCN-AML-2025SRC-ELN-AML-2022SRC-ESMO-AML-2020
AML with FLT3-ITD or FLT3-TKD mutation — addition of midostaurin (or gilteritinib in r/r) to induction is required (RATIFY trial)
Triggers addition of midostaurin 50 mg PO BID days 8-21 to 7+3 induction + HiDAC consolidation in fit patients. Gilteritinib is the r/r-AML standard. NOT applicable for unfit patients on ven+aza (FLT3-targeting in that setting under…
RF-AML-FLT3-ACTIONABLESRC-NCCN-AML-2025SRC-RATIFY-STONE-2017SRC-ELN-AML-2022
IDH2 R140Q or R172K activating mutation in AML — ~8-12% prevalence. Enasidenib (IDHIFA / IDHENTIFY — phase-3 R/R AML; monotherapy ORR 38%, CR 19%) is FDA-approved for R/R-AML-IDH2; also active 1L combination with azacitidine in unfit (AG221-AML-005 — ORR 71%).
Detection: NGS panel (no IDH2-specific IHC widely deployed). Differentiation syndrome on enasidenib (~14%) — same monitoring + dexamethasone protocol as ivosidenib. Hyperbilirubinemia on enasidenib (~80% any grade; UGT1A1 inhibition —…
RF-AML-IDH2-MUT-ACTIONABLESRC-NCCN-AML-2025SRC-ELN-AML-2022SRC-ESMO-AML-2020
AML patient with positive HBV / HCV / HIV serology, latent TB, or active uncontrolled infection — needs antiviral prophylaxis (HBV-active prophylaxis with entecavir/tenofovir; HCV expert consult; ART optimization for HIV; TB treatment) before induction
Direction "hold" surfaces a workup-prerequisite annotation. AML induction (anthracycline + cytarabine) and ven+aza both cause profound immunosuppression with high HBV-reactivation risk if HBsAg+ or anti-HBc+ without prophylaxis. HBV…
RF-AML-INFECTION-SCREENINGSRC-NCCN-AML-2025SRC-ELN-AML-2022
KMT2A rearrangement (MLL fusion at 11q23) in AML — ~5-10% prevalence in adult AML; ELN-2022 adverse-risk classifier. Revumenib (menin inhibitor; AUGMENT-101 phase 1/2) FDA-approved Nov 2024 for relapsed/ refractory KMT2A-rearranged acute leukemia after ≥1 prior line (ORR ~63%, CR/CRh ~23%). Ziftomenib alternative menin inhibitor in late-phase trials. Common partners: AF9 (t(9;11)) and AF4 (t(4;11)).
Detection: karyotype + FISH break-apart probe at diagnosis; RT-PCR or RNA-NGS for fusion partner identification. Differentiation syndrome on revumenib (~16%) — monitor for fever, dyspnea, weight gain, effusions; treat with dexamethasone +…
RF-AML-KMT2A-ACTIONABLESRC-NCCN-AML-2025SRC-ELN-AML-2022

CONTRA-AGGRESSIVE

Hard contraindications to escalation

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Aggressive plan (IND-AML-2L-IDH2-ENASIDENIB)

Do NOT prescribe without confirmation of IDH2 R140Q or R172K mutation (NGS panel) — enasidenib is not active in IDH2-WT.
Do NOT skip differentiation syndrome education + corticosteroid kit — fatal without immediate dexamethasone.
Do NOT declare non-response earlier than 6 cycles — median time to first response ~1.9 months; slow kinetics.
Do NOT automatically reduce dose for hyperbilirubinemia — if asymptomatic (UGT1A1 inhibition), continue without change.
Do NOT consider as curative monotherapy — bridging to alloHSCT is mandatory for fit responders.
Do NOT combine with strong CYP3A4 inducers without monitoring — reduced exposure.
Do NOT confirm the plan without funding pathway — drug not registered in Ukraine; EU CHMP negative.

Aggressive plan (IND-AML-2L-GILTERITINIB-FLT3)

Do NOT prescribe without re-testing FLT3 at the time of relapse — FLT3 clone can disappear or evolve; ~25% relapse-loss FLT3.
Do NOT skip baseline + serial ECG + electrolyte correction (K+ ≥4.0, Mg++ ≥2.0) — torsades documented.
Do NOT ignore differentiation syndrome (fever, dyspnea, weight gain, pleural effusion) — fatal without dexamethasone.
Do NOT consider as curative monotherapy — bridging to alloHCT is mandatory for fit responders.
Do NOT combine with strong CYP3A4-inhibitors without dose reduction + intensive QTc monitoring.
Do NOT discontinue on transient cytopenia — recovery is often slow; G-CSF + transfusion support as needed.
Do NOT confirm the plan without funding pathway — drug not registered in Ukraine.

Aggressive plan (IND-AML-2L-KMT2A-REVUMENIB)

Do NOT prescribe without confirmation of KMT2A rearrangement at the time of relapse — karyotype + FISH break-apart mandatory.
Do NOT skip baseline + serial ECG + electrolyte correction (K+ ≥4.0, Mg++ ≥2.0) — QTc prolongation documented.
Do NOT ignore differentiation syndrome (fever, dyspnea, weight gain, pleural effusion, leukocytosis) — fatal without dexamethasone + cytoreduction.
Do NOT consider as curative monotherapy — bridging to alloHSCT is mandatory for fit responders.
Do NOT combine with strong CYP3A4 inducers — substantial reduction in exposure; avoid.
Do NOT confirm the plan without funding pathway — drug not registered in Ukraine (Syndax EAP / cross-border only).

Standard plan (IND-AML-1L-VEN-AZA)

Do not skip the 3-day venetoclax ramp + TLS prophylaxis — fatal TLS cases described when skipping the ramp.
Do not use full-dose venetoclax (400 mg) with a strong CYP3A4 inhibitor (azole) — reduction to ~70-100 mg required.
Do not skip HBV screening + prophylaxis — reactivation on HMA + venetoclax described.
Do not expect a rapid response — azacitidine requires 4-6 cycles; do not stop earlier without progression.
Do not skip G-CSF in febrile neutropenia — cumulative cytopenias expected; antimicrobial prophylaxis is mandatory.

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Aggressive plan

Induction · Enasidenib monotherapy for R/R IDH2-mutated AML

28-day cycles × Continuous until progression / unacceptable toxicity; proceed to alloHCT in fit responders. Continue ≥6 cycles before declaring non-response (median time to first response ~1.9 mo).

Aggressive plan

Induction · Gilteritinib monotherapy for R/R FLT3-mutated AML

28-day cycles × Continuous until progression / unacceptable toxicity / proceed to alloHCT in CR

Aggressive plan

Induction · Revumenib monotherapy for R/R KMT2A-rearranged AML

28-day cycles × Continuous until progression / unacceptable toxicity; proceed to alloHCT in fit responders

Standard plan

Induction · Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule

28-day cycles × Continue until progression / unacceptable toxicity (median ~12 cycles in VIALE-A; ~25-30% achieve durable remission)

MDT brief

Discussion questions (1, 0 blocking)

OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist

MDT talk tree (2 steps)

#	Owner	Topic	Action
1	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
2	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (recommended) — for consideration (1)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 0/0 known (100%), 0 missing, 0 default-track gaps
Unevaluated RedFlags: RF-AML-CD33-POS-GO-CANDIDATE, RF-AML-CORE-BINDING-FACTOR-FAVORABLE, RF-AML-EMERGENCY-TLS-LEUKOSTASIS, RF-AML-FLT3-ACTIONABLE, RF-AML-FRAILTY-AGE, RF-AML-HIGH-RISK-BIOLOGY, RF-AML-IDH1-MUT-ACTIONABLE, RF-AML-IDH2-MUT-ACTIONABLE, RF-AML-INFECTION-SCREENING, RF-AML-KMT2A-ACTIONABLE, RF-AML-MEASURABLE-RESIDUAL-DISEASE, RF-AML-NPM1-MUT-FAVORABLE, RF-AML-ORGAN-DYSFUNCTION, RF-AML-SECONDARY-AML-MRC-CPX351-ELIGIBLE, RF-AML-TP53-ADVERSE, RF-AML-TRANSFORMATION-PROGRESSION, RF-ANKRD26-CONFIRMED-CARRIER, RF-CASCADE-LFS-FDR-POSITIVE, RF-CEBPA-CONFIRMED-CARRIER, RF-DDX41-CONFIRMED-CARRIER, RF-ETV6-CONFIRMED-CARRIER, RF-IATROGENIC-ALKYLATOR-TAML-PREVENTION, RF-IATROGENIC-ANTHRACYCLINE-CARDIO-PREVENTION, RF-IATROGENIC-ANTHRACYCLINE-LATE-CARDIO-PREVENTION, RF-IATROGENIC-ASCT-SECONDARY-MDS-AML-PREVENTION, RF-IATROGENIC-PLATINUM-LATE-PREVENTION, RF-IATROGENIC-PRIOR-RADIATION-PREVENTION, RF-IATROGENIC-TOPO2-TAML-PREVENTION, RF-LI-FRAUMENI-CONFIRMED-CARRIER, RF-LI-FRAUMENI-FAMILY-HISTORY-SUSPICION, RF-LIFESTYLE-TOBACCO-CANCER-PREVENTION, RF-MPN-SECONDARY-LEUKEMIA-PREVENTION, RF-OCC-BENZENE-MALIGNANCY-PREVENTION, RF-OCC-FORMALDEHYDE-PREVENTION, RF-OCC-IONIZING-RADIATION-PREVENTION, RF-OCC-PAINTERS-PREVENTION, RF-RUNX1-CONFIRMED-CARRIER

Technical MDT skill metadata (1/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-ADMIRAL-PERL-2019: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML (2019)
SRC-ELN-AML-2022: Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel (2022)
SRC-ESMO-AML-2020: Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020)
SRC-NCCN-AML-2025: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (v.X.2025)
SRC-VIALE-A-DINARDO-2020: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (2020)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-07-15.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT07059975	UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML	EARLY_PHASE1	RECRUITING	Joanna Yi	—	Small N (<50) Single country
NCT07198867	A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING	First Affiliated Hospital of Zhejiang University	—	Phase 1 only Small N (<50) Single country
NCT05503134	Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML	PHASE1 / PHASE2	RECRUITING	Nationwide Children's Hospital	—	Small N (<50) Single country
NCT06510868	Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy	N/A	RECRUITING	University Health Network, Toronto	—	Small N (<50) Single country
NCT03854318	Longitudinal Studies of Patient With FPDMM	N/A	RECRUITING	National Human Genome Research Institute (NHGRI)	—	Single country
NCT07254312	Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.	N/A	RECRUITING	Fondazione IRCCS Policlinico San Matteo di Pavia	—	Small N (<50) Single country
NCT07356154	A Study of Revumenib and Mezigdomide in People With Leukemia	PHASE1 / PHASE2	RECRUITING	Memorial Sloan Kettering Cancer Center	—	Single country
NCT06994676	A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias	PHASE1	RECRUITING	Crossbow Therapeutics, Inc.	—	Phase 1 only Single country
NCT06459024	Master Framework For Relapse or Refractory Acute Myeloid Leukemia	N/A	RECRUITING	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	—	—
NCT06886425	Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies	NA	RECRUITING	Assistance Publique Hopitaux De Marseille	—	Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Aggressive plan Enasidenib monotherapy for R/R IDH2-mutated AML (REG-ENASIDENIB-AML) 1/1 component drug(s) not registered in Ukraine +1	✗ not registered	✗ out-of-pocket	₴-? — verify pathway	not recorded
Aggressive plan Gilteritinib monotherapy for R/R FLT3-mutated AML (REG-GILTERITINIB-AML) 1/1 component drug(s) not registered in Ukraine +1	✗ not registered	✗ out-of-pocket	₴-? — verify pathway	not recorded
Aggressive plan Revumenib monotherapy for R/R KMT2A-rearranged AML (REG-REVUMENIB-AML) 1/1 component drug(s) not registered in Ukraine +1	✗ not registered	✗ out-of-pocket	₴-? — verify pathway	not recorded
Standard plan Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule (REG-VEN-AZA-AML)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT07059975 UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07198867 A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05503134 Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06510868 Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03854318 Longitudinal Studies of Patient With FPDMM No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07254312 Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission. No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07356154 A Study of Revumenib and Mezigdomide in People With Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06994676 A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06459024 Master Framework For Relapse or Refractory Acute Myeloid Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06886425 Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-07-15.

plan_id: PLAN-VERIFIED-AML-L2-AML_2L_IDH2_ENASIDENIB-V1 | version: 1 | generated: 2026-07-15T13:33:22.833948+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.